Alpha 2.0
Login Register
» Authors » Kirsten C Refvik

Kirsten C Refvik

Explore the profile of Kirsten C Refvik including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 8
Followers 0
Related Specialties
Biology
General Medicine
Biomedical Engineering
Top 10 Co-Authors
Aaron T Alpar
Jeffrey A Hubbell
Anna J Slezak
Ani Solanki
Rachel P Wallace
Abigail L Lauterbach
Suzana Gomes
Aslan Mansurov
Jun Ishihara
Taryn N Beckman
Published In
NPJ Regen Med
bioRxiv
Cell Rep Med
J Immunother Cancer
Blood Adv
Affiliations
Soon will be listed here.
Recent Articles
1.
Engineered GM-CSF polarizes protumorigenic tumor-associated macrophages to an antitumorigenic phenotype and potently synergizes with IL-12 immunotherapy
Kang S, Mansurov A, Kurtanich T, Chun H, Slezak A, Volpatti L, et al.
J Immunother Cancer . 2025 Jan; 12(12). PMID: 39794939
Background: The use of immune checkpoint inhibitors (CPIs) has become a dominant regimen in modern cancer therapy, however immune resistance induced by tumor-associated macrophages (TAMs) with immune suppressive and evasion...
2.
A serine-conjugated butyrate prodrug with high oral bioavailability suppresses autoimmune arthritis and neuroinflammation in mice
Cao S, Budina E, Raczy M, Solanki A, Nguyen M, Beckman T, et al.
Nat Biomed Eng . 2024 Apr; 8(5):611-627. PMID: 38561491
Butyrate-a metabolite produced by commensal bacteria-has been extensively studied for its immunomodulatory effects on immune cells, including regulatory T cells, macrophages and dendritic cells. However, the development of butyrate as...
3.
Cysteine-binding adjuvant enhances survival and promotes immune function in a murine model of acute myeloid leukemia
Slezak A, Chang K, Beckman T, Refvik K, Alpar A, Lauterbach A, et al.
Blood Adv . 2024 Feb; 8(7):1747-1759. PMID: 38324726
Therapeutic vaccination has long been a promising avenue for cancer immunotherapy but is often limited by tumor heterogeneity. The genetic and molecular diversity between patients often results in variation in...
4.
Synthetically mannosylated antigens induce antigen-specific humoral tolerance and reduce anti-drug antibody responses to immunogenic biologics
Wallace R, Refvik K, Antane J, Brunggel K, Tremain A, Raczy M, et al.
Cell Rep Med . 2023 Dec; 5(1):101345. PMID: 38128533
Immunogenic biologics trigger an anti-drug antibody (ADA) response in patients that reduces efficacy and increases adverse reactions. Our laboratory has shown that targeting protein antigen to the liver microenvironment can...
5.
Engineered IL-7 synergizes with IL-12 immunotherapy to prevent T cell exhaustion and promote memory without exacerbating toxicity
Kang S, Mansurov A, Kurtanich T, Chun H, Slezak A, Volpatti L, et al.
Sci Adv . 2023 Nov; 9(48):eadh9879. PMID: 38019919
Cancer immunotherapy is moving toward combination regimens with agents of complementary mechanisms of action to achieve more frequent and robust efficacy. However, compared with single-agent therapies, combination immunotherapies are associated...
6.
Author Correction: Topically-applied collagen-binding serum albumin-fused interleukin-4 modulates wound microenvironment in non-healing wounds
Lauterbach A, Wallace R, Alpar A, Refvik K, Reda J, Ishihara A, et al.
NPJ Regen Med . 2023 Nov; 8(1):62. PMID: 37919358
No abstract available.
7.
Topically-applied collagen-binding serum albumin-fused interleukin-4 modulates wound microenvironment in non-healing wounds
Lauterbach A, Wallace R, Alpar A, Refvik K, Reda J, Ishihara A, et al.
NPJ Regen Med . 2023 Sep; 8(1):49. PMID: 37696884
Non-healing wounds have a negative impact on quality of life and account for many cases of amputation and even early death among patients. Diabetic patients are the predominate population affected...
8.
Synthetically mannosylated antigens induce antigen-specific humoral tolerance and reduce anti-drug antibody responses to immunogenic biologics
Wallace R, Refvik K, Antane J, Brunggel K, Tremain A, Raczy M, et al.
bioRxiv . 2023 Apr; PMID: 37066302
Immunogenic biologics trigger an anti-drug antibody (ADA) response in patients, which reduces efficacy and increases adverse reactions. Our laboratory has previously shown that targeting protein antigen to the liver microenvironment...